Combination chemotherapy with paclitaxel and platinum in the treatment for advanced or recurrent ovarian clear cell adenocarcinoma: Multicenter trial

Abstract

5101 Background: Patients with clear cell adenocarcinoma of the ovary (CC) have a poor response to chemotherapy and have a significantly worse prognosis than other histological types of ovarian cancer. However, the therapeutic effect of a combination of paclitaxel (PTX) and platinum (PLT) in CC patients with measurable disease has yet to be elucidated. In this study, we evaluated the treatment results of a combination of PTX and PLT in CC patients with measurable disease by retrospective review. Methods: Twenty–eight patients with measurable residual CC (12 primary cases and 16 recurrent cases), who were treated with combination chemotherapy with PTX and PLT, were identified through the medical records from 10 institutions. Patients with serous adenocarcinoma were selected as a control for comparison. Histological evaluation was performed under the central pathological review. Clinical response to chemotherapy was compared between CC and serous adenocarcinoma patients using RECIST criteria. Results: In primary cases, 7 of 12 CC patients (58.3%) and 17 of 22 serous adenocarcinoma patients (77.3%) responded to chemotherapy, and the difference was not significant. In recurrence CC cases, 3 of 16 CC patients (18.8%) responded to the chemotherapy. The difference of response rate between primary and recurrent cases in CC patients was statistically significant (P<0.05). Conclusion: The response rate of this combination chemotherapy for primary residual CC patients was relatively high and was comparable with those of serous adenocarcinoma. Our results indicate that the combination of PTX and PLT has a sufficient potential as first–line chemotherapy to this ‘assumed’ chemo–resistant tumor. No significant financial relationships to disclose.